U.S. Tariffs Threaten Swedish Pharmaceutical Supply Chain

Recent announcements by U.S. President Donald Trump regarding significant tariffs on pharmaceuticals have raised alarms in Sweden’s healthcare sector. Sofia Wallström, CEO of Lif, representing the pharmaceutical industry, warns that these tariffs could lead to drug shortages and increased prices for patients in Sweden. At a government meeting, Trump suggested tariffs might reach up to 200% for companies that do not relocate production to the U.S. within a year, jeopardizing the existing global supply chains Sweden depends on for essential medicines, including critical cancer treatments.

Wallström emphasized the consequences of these tariffs, stating they could exacerbate current medication shortages and inflate production costs by impacting the supply of active pharmaceutical ingredients (APIs) from countries like China and India. As a result, directly passing these expenses onto patients in Sweden could become unavoidable, compounding the existing challenges in healthcare accessibility.

Simultaneously, the broader implications of the tariffs on Swedish exports have been highlighted, with over 135,000 jobs linked to exports to the U.S., the country's largest export market. With an 8% decline in exports reported from January to May compared to last year, industries like pharmaceuticals are bracing for potential job losses and decreased manufacturing activity due to these tariffs. Michael Koch of Kommerskollegium noted the pressing need for Sweden to seek alternative markets to mitigate the risks associated with increasing tariffs on exports.